pharmaceutically-acceptable
alcohol per volume of formulation, 12-18% weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation
and a sufficient amount of a ricinoleate vehicle so as to prepare
a formulation of at least 45 mgml-1 of fulvestrant.
with dependent claims 25 to 31 to remain unchanged.
3. Auxiliary to no. 2 above, the Patent is to be upheld with the following
limited claims:
1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration to human patients, wherein the formulation